Following the committee meeting on 11 April 2018, there were internal discussions and as a consequence we were unable to release the appraisal consultation document (ACD) for this appraisal. We have contacted clinical experts to clarify the issues identified during the development of the ACD. In addition, the company has requested to submit a new value proposition for lutetium. We will therefore not be issuing the ACD that was developed at this stage. The appraisal committee will consider this additional evidence and continue its deliberations on Tuesday 12 June 2018.